IBP Stock +106.23% Since Nov ’07 Pick IBP Stock +106.23% Since Nov ’07 Pick Unlock Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -1.923 1 day ( 0 % )
Last Price $1.82 -5.21 %
High/ Low $1.81 - $1.98 9.93%
Chg 7 Days -9.90 % $2.02 $1.82
Chg 30 Days 18.18 % $1.54 $1.82
Chg 12 mos -31.32 % $2.65 $1.82
Trend - 3 mos -50.80 % Width: 497.10 %
Trend - 12 mos 8.84 % Width: 261.25 %
Pred. range - 3 mos $0.239 - $1.43 -86.87 % - -21.61 %
Pred. range - 12 mos $1.67 - $6.05 -8.03 % - 232.23 %
Short MA avg 3 mos Sell 2024-04-12 - 2 days
Long MA avg 3 mos Buy 2024-04-08 - 6 days
Short/Long MA avg 3 mos Buy 2024-04-12 - 2 days
Short MA avg 12 mos Buy 2024-03-27 - 13 days
Long MA avg 12 mos Sell 2024-02-27 - 34 days
Short/Long MA avg 12 mos Sell 2024-03-11 - 25 days
Pivot Short Buy 2024-03-14 - 22 days
Bollinger Buy 2023-12-04 - 91 days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Palatin Technologies Inc

Palatin Technologies Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatmen... PTN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT